started the first BPC-157 cycle Oct 2024 after the VA MRI wait finally cleared. 19 months later, here’s what the log actually shows vs what i was hoping for going in. baseline Oct 2024: couldn’t squat below parallel without a 2-day flare. pain at rest 3-4/10. ROM on the bad knee measured 118 degrees flexion. cycle 1 (Oct-Nov 2024): 250mcg subq split AM/PM, 4 weeks, pin sites rotated around the joint. clicking gone by wk 3. pain at rest dropped to 1-2/10 by end of cycle. gap to cycle 2 was longer than i wanted, 5 months, bc i wanted to see what held without the compound on board. cycle 2 (Apr-May 2025): same dose, added TB-500 2mg weekly. ROM hit 135 by end. squat below parallel without next-day flare for the first time in maybe 7 years. what the numbers don’t tell you: i still can’t load it the way i could at 45. function gains are real but i hit a ceiling around wk 3 of cycle 2 that didn’t move. wondering now if that ceiling is the hyponeural piece i was sitting with after the Botox thread. if innervation is the bottleneck, BPC operates downstream of it and i’m reading 70% as 100%. ymmv. n=1, one knee, one body.
“reading 70% as 100%” is the right frame, but the TB-500 addition in cycle 2 creates a confound that makes the ceiling question harder to parse than it might look. Both compounds are on board when you hit the wk 3 plateau, and TB-500’s systemic actin sequestration has a different saturation profile than BPC’s local tissue activity, so you can’t cleanly separate a collagen remodeling ceiling from a TB-500 saturation effect from the hyponeural bottleneck you’re pointing at. The innervation hypothesis is mechanistically plausible (BPC’s growth factor signaling doesn’t directly address nerve regrowth or remyelination), but without a solo-BPC cycle you’re not going to disentangle it from the other two explanations. What I’d want from the 5-month gap data specifically: did rest pain hold at 1-2/10 going into cycle 2, and did the clicking stay suppressed the whole time? Because if both held without the compounds on board, that’s durability data that changes what “ceiling” actually means in this context.
The innervation bottleneck hypothesis is worth sitting with, and 19 months of tracked markers gives you more to reason from than most people have. But “BPC operates downstream of it” isn’t quite right based on the animal literature - there’s direct vagal nerve interaction in the mechanism data, which puts BPC partly in the neural space, not only at the tissue level below it. The ceiling may still be real, but if BPC has some neural activity of its own, the framing changes what you’d need to add to actually move past it.
rest pain held at 1-2 by month 3 of the gap then crept to 2-3 by month 5, clicking stayed gone the whole stretch. you’re right that i can’t separate the three without a solo-BPC cycle and i didn’t run one, which means the ceiling read is doing more work than the data supports.
“reading 70% as 100%” is the part that stuck with me. if innervation really is the ceiling and BPC is downstream of it, you’d expect the gains to look almost identical to yours: real, meaningful, then a wall that doesn’t budge no matter how clean the protocol is. the question i’d sit with is whether the ceiling shifted at all between cycle 1 and cycle 2, or held at exactly the same point
reading through your log carefully because the methodology here is better than most of what gets posted, and the 5-month gap was the right call even if it felt long. baseline 118 to 135 ROM with a real squat-below-parallel marker is a clean readout, not the vague “feels better” most people stop at. the part I’d gently push on is the hyponeural framing as the explanation for the wk 3 ceiling. the neural inhibition mechanism has reasonable RCT support for skin (keloid, burn remodeling, where dermal innervation is genuinely operative), but the transfer into knee joint tissue is where the argument stops landing the same way. for the meniscus, cartilage, and ligamentous structures around a knee, the rate-limiting steps for further remodeling at this stage are collagen crosslink reorganization and vascular bed maturity, not innervation density. that’s not me saying neural input is irrelevant to the joint, it’s saying it’s likely not the bottleneck holding your wk 3 ceiling where you think it is. worth pushing on this too: by cycle 2 your right knee tissue isn’t naive anymore. it carries the architectural footprint of cycle 1, even with a 5-month gap and partial functional regression. re-degraded tissue still has shifted crosslink pattern, vascular bed density, fibroblast population from the prior remodel. so the per-week gain you’re measuring in cycle 2 is already scaling against partially-organized tissue, which means a wk 3 plateau in cycle 2 doesn’t map onto a wk 3 plateau in cycle 1 the way it looks like it should on paper. functional regression and architectural reset are different variables, and the ceiling you’re hitting might just be where this knee’s tissue maturation state actually sits at 19 months in, not a missing mechanism. the “i still can’t load it the way i could at 45” piece is probably honest and worth sitting with separately. at 45 to now, you’re looking at sarcopenia trajectory, tendon stiffness changes, motor unit loss that BPC and TB-500 aren’t pointing at. that’s not a peptide ceiling, that’s a different conversation about training load and recovery architecture. either way, the log itself is solid work.
Calling out the ceiling read as overextended is the right move, but I’d push back gently on treating the gap period as analytically inert. Rest pain holding at 1-2 for three months then creeping to 2-3 by month 5 is a rough decay curve on the BPC contribution, not a controlled comparison but not nothing. It gives you some window into how long the solo effect held before it attenuated. That’s more usable data than most people’s anecdotal “I stopped and it came back” reporting. I track between-cycle drift in CareClinic’s daily check-in specifically because that slow creep is where the durability question actually lives, and 60 days of timestamped entries catches what memory tends to flatten into “it was fine until it wasn’t.”
the ceiling hitting at wk 3 of cycle 2 is the part i’d push back on as evidence of an innervation bottleneck. wk 3 is where the angiogenic and fibroblast-recruitment use of BPC is already past peak in tissue that’s been worked on across two cycles, and 5 months between cycles doesn’t reset that to naive. the architectural footprint of cycle 1 is still there in your crosslink pattern and vascular bed, so what you’re calling a ceiling at 70% might just be the diminishing-returns slope of already-organized tissue, not a separate hyponeural variable sitting underneath. the innervation argument got extended into joint and tendon work off the Botox skin RCTs, but the mechanism transfer isn’t clean. in skin the neural inhibition story has at least small RCT support in keloid and burn. in knee joint tissue the rate-limiting steps for the kind of loading you’re describing are collagen organization and how the patellar tendon and quad insertion handle eccentric demand, not innervation density. so before reading 70% as 100%, i’d want to know what the eccentric tolerance curve looks like on the bad side vs the good side at matched load. if eccentric capacity is the gap, that’s a loading and tendon adaptation problem, not a downstream-of-innervation problem. ymmv, your log is cleaner than mine.
Arthrogenic muscle inhibition is the piece I’d add to the picture before you settle on hyponeural as the ceiling. AMI is the reflex inhibition of the quad that gets switched on by joint effusion, capsular irritation, or pain, and the literature on it post-meniscus and post-ACL is fairly mature. Even a small residual effusion that you don’t visually notice can keep VMO activation down by 15 to 20 percent on EMG comparisons against the uninvolved side, and the quad will quietly load-share badly without the knee feeling unstable to you. The reason I bring it up is that the loading ceiling you describe, function returns but the knee won’t accept the weight it used to, is exactly the pattern AMI produces. BPC and TB-500 are operating on tissue substrate. Neither one reaches the spinal reflex arc that’s keeping the quad under-recruited. The test that actually pulls it apart is single-leg quad strength against the good leg, ideally on a dynamometer if your PT has one but a leg extension max works as a rough proxy. If the involved side is sitting below about 90 percent of the contralateral at this point, AMI is still probably in the mix and that’s a different intervention pathway than anything peptide-based. NMES on the quad, blood flow restriction at low loads, and aggressive effusion management are the standard tools and they target the reflex loop directly. There was a thread a few months back on someone running BFR for post-surgical quad recovery that had useful protocol detail if it’s worth chasing. Two BPC cycles plus a TB-500 add adds real variables to your log, but the ceiling itself might be sitting at a different level of the system than where the compounds are working. Not arguing against the hyponeural read, just noting there’s an intermediate layer between innervation and tissue that’s worth ruling out first because it has a known intervention.
“reading 70% as 100%” is the right framing, but the ceiling at wk 3 of cycle 2 also lines up with where most BPC mechanism arguments stop having anything new to say, so the bottleneck could be downstream of innervation too. either way you need a non-BPC variable to test it, otherwise cycle 3 is just confirming the same ceiling.
adding TB-500 in cycle 2 makes the ceiling impossible to read - you can’t tell if BPC hit a plateau or if the second peptide shifted what the system is responding to. ROM and load capacity are mechanically separate problems, and they probably need completely different stimulus. isolating which one is actually hitting the wall would tell you whether innervation is the bottleneck or if that’s just where these compounds max out on loaded function.
the hyponeural-as-ceiling read is the part I’d push on, gently, because the timing doesn’t quite fit. you hit the plateau at wk 3 of cycle 2, which is also right around when within-vial degradation on a multi-puncture BPC vial starts to bite if it’s been sitting reconstituted at 4C for 21+ days. pentadecapeptide is more forgiving than a lot of peptides but it isn’t immune, and the aggregation curve over a 4-week vial life is exactly the kind of slow drift that gets read as “the compound stopped working on me” when it might be “the compound at wk 3 is not the same compound that was in the syringe on day 1.” worth knowing before you assign the ceiling to innervation, because the two hypotheses point at different next moves (fresh vial vs. EMG referral). the rest of the log is genuinely tidy and i don’t want to take away from that. ROM 118 to 135 over two cycles with a 5-month washout between them is the kind of n=1 that actually tells you something, because you let it run unmedicated long enough to see what held, which most people don’t. the “can’t load it the way i could at 45” piece may also just be 70 years of cartilage doing what cartilage does, independent of either pathway.
the innervation angle makes more sense to me than most plateau explanations i’ve read at this timeline - if the signal pathway itself is compromised, downstream repair tools just run into the wall regardless of tissue quality. but cycle 2 added TB-500 at 2mg weekly, and that’s a real confound when you’re trying to locate where the ceiling is coming from. the ROM jump from 118 to 135 could be TB-500 driving matrix remodeling while BPC was already past its window on the neural piece - which means “reading 70% as 100%” might actually be reading two compounds doing different jobs and one of them running out of runway first, not innervation alone. curious whether a solo BPC cycle 3 holds the same plateau or moves, bc that’s the cleaner read on which variable actually hit the wall.
the innervation borrow from the botox thread is where i’d slow down. that argument held because tendons and labrums are hyponeural and hypovascular by design, so nerve-blocking or angiogenesis mechanisms have less to grab onto. a knee is a synovial joint with a well innervated capsule and ligaments, it’s not the same tissue class, so importing “innervation is the bottleneck” from a labrum thread to a knee is a bigger leap than it reads. the other thing: you hit the ceiling “around wk 3 of cycle 2.” on bpc, wk 3-4 is a hint, not a signal, the real depth tends to show wk 5-7. a flat reading at wk 3 might be a timing artifact, not a structural limit, and you may have called the ceiling before the compound finished talking. and cycle 2 added TB-500 2mg weekly, so the jump to 135 ROM has two variables in it. real gain, but you can’t cleanly hand it to either one. fwiw the function numbers are still solid, i’d just be slower to file the plateau under innervation.